Trials
10 active
11 in total · 8 in the EU
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- How it’s given
- “Participants will receive cevostamab IV as per the schedule given in the protocol.”In the company’s words, NCT07555938 on ClinicalTrials.gov
- Tested for
- Multiple Myeloma (7 trials), Relapsed or Refractory Multiple Myeloma, Lupus Erythematosus, Systemic, Relapsed Multiple Myeloma, Refractory Multiple Myeloma
- Main trialPhase 3
- “The purpose of this study is to assess the efficacy and safety of cevostamab in combination with pomalidomide and dexamethasone (CevosPd) versus standard of care (SOC) in participants with multiple myeloma (MM) who have received one to three prior lines of therapy and have been exposed to an anti-CD38 monoclonal antibody (mAb) and lenalidomide.”In the company’s words, NCT07555938 on ClinicalTrials.gov
- Other names
- RO7187797
Other drugs for Multiple Myeloma
- MezigdomideCelgene · Phase 3
- Anitocabtagene-autoleucelGilead (Kite) · Phase 3
- CM336Keymed Biosciences Co.Ltd · Phase 3
- IBI3003Innovent · Phase 3
- PomalidomideCelgene · Phase 3
- DaratumumabJanssen Research & Development, LLC · Phase 3
Coming up10
- 18 NovPhase 1 trial completes · ClinicalTrials.gov
- 26 Feb 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 31 Jul 2027Phase 1 trial completes · ClinicalTrials.gov
- 31 Jul 2028Phase 1/2 trial completes · ClinicalTrials.gov
- 15 Nov 2028Phase 1 trial completes · ClinicalTrials.gov
- 30 Nov 2028Phase 3 trial completes · ClinicalTrials.gov
- 21 Dec 2028Phase 1 trial completes · ClinicalTrials.gov
- 13 Apr 2029Phase 2 trial completes · ClinicalTrials.gov
- 29 Mar 2030Phase 1 trial completes · ClinicalTrials.gov
- 17 Jun 2030Phase 1 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 18 NovCompletion date moved: 2028-10-31 to 2028-11-30 · ClinicalTrials.gov NCT07555938
Trials11
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 30 Nov 2028 | Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma | |
| Phase 2Recruiting | 13 Apr 2029 | Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma | |
| Phase 1/2Active, not recruiting | 26 Feb 2027 | A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma | |
| Phase 1/2Recruiting | 31 Jul 2028 | A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma | |
| Phase 1Active, not recruiting | 18 Nov 2026 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma | |
| Phase 1Recruiting | 31 Jul 2027 | A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) | |
| Phase 1Active, not recruiting | 15 Nov 2028 | A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma | |
| Phase 1Recruiting | 21 Dec 2028 | A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma | |
| Phase 1Recruiting | 29 Mar 2030 | To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis | |
| Phase 1Active, not recruiting | 17 Jun 2030 | A Clinical Study to Evaluate the Effects of RO7875913 in Healthy Participants and of RO7875913 With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma | |
| Phase 1Completed | 7 Jan 2026 | Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026